The numbers studied
Ipamorelin dosage, as the studies recorded it: which doses went into which species, by which route — not a protocol.
Every figure here is a study parameter reported in third person. Nothing on this page is a recommendation.
Start here
A clear note before any number appears: this page reports the doses and routes that researchers used in studies — in people and in animals. It is a record of the literature, not a how-to. There is no approved ipamorelin dose anywhere in the world, no human protocol with controlled-trial support, and nothing here tells anyone what to take. The community "stack" regimens that pair ipamorelin with CJC-1295 have no peer-reviewed human dosing basis and are described as anecdotal where they come up. What the studies do tell us is concrete and worth knowing: ipamorelin clears fast (a roughly 2-hour half-life in people), produces a single growth-hormone pulse about 40 minutes after dosing [2], and has been given by several routes across species. Those facts follow, attributed to the studies that measured them.
Doses recorded in the human studies
Two human datasets define the entire controlled record. The pharmacokinetic study used single intravenous infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes in healthy male volunteers, eight per dose level [2]. The Phase 2 ileus trial used 0.03 mg/kg intravenously twice daily for up to 7 days in 114 bowel-resection patients [3]. Both were intravenous and clinic-administered. Neither establishes a dose for any wellness use — the PK study only characterized kinetics, and the Phase 2 trial missed its endpoint [3]. There is no human subcutaneous dosing study at all, despite subcutaneous injection being the dominant route in off-label use.
Doses recorded in the animal studies
The animal record spans a wider dose and route range. The rat bone-growth study used 18, 90, and 450 micrograms per day subcutaneously, divided three times daily for 15 days [4]. A separate rat bone-mineral study used 0.5 mg/kg per day by continuous subcutaneous osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1–1 mg/kg intravenously, repeated four times daily. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. The ipamorelin-derived oral analog NN703 was dosed at 100 micromol/kg/day orally for 14 days in rats [11]. These are model parameters — chosen to probe a mechanism in a species, not to map onto human use.
Half-life and routes studied
In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours by the intravenous route, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg; the GH response was a single discrete pulse peaking near 40 minutes [2]. In rats, plasma clearance runs roughly five-fold lower than GHRP-6. Routes that appear in the literature include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant community route), intranasal (rodent PK, around 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable — only engineered analogs such as NN703 achieve meaningful oral absorption (around 10–30% in dogs) [11].
How much cjc-1295 ipamorelin should i take
No published human study establishes a dose for the CJC-1295 plus ipamorelin combination, so there is no evidence-based answer to this question and this page does not provide one [3]. The popular subcutaneous "stack" regimens circulating in community forums have no controlled human dosing basis and rest on each peptide's separate pharmacology, not on any trial of the pair [7]. What the literature does establish — the human ipamorelin doses studied — is that the controlled record consists only of intravenous, clinic-administered protocols [2][3], none of which were designed as wellness dosing. Anyone encountering a specific milligram figure online should recognize it as anecdotal, not a researched dose.
How to reconstitute cjc-1295 ipamorelin 5mg
As a general matter of peptide handling in the research-supply literature, ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and reconstituted with bacteriostatic water for research handling, after which the solution is typically kept refrigerated because peptides degrade with heat and repeated freeze-thaw. Those are general handling observations, not a clinical preparation instruction, and no specific reconstitution volume or concentration is endorsed here. There is no published human protocol for a CJC-1295 plus ipamorelin preparation [3]; the combination's handling, like its dosing, exists only in unregulated community practice rather than in the peer-reviewed literature.